The safety and efficacy of Aprepitant to the prevention of chemotherapy-induced nausea and vomiting

The safety and efficacy of Aprepitant to prevent chemotherapy-induced nausea and vomiting in children with cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200819048455N1

Enrollment

Registered

2020-09-13

Start date

2020-05-30

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant cancer. Malignant neoplasms

Interventions

Intervention group: A total of 85 children with cancer who are candidates for chemotherapy receive Ondansetron (produced by Exir Company, Iran) thirty minutes before treatment intravenously at a dose

Eligibility

Sex/Gender

All

Age

6 Months to 17 Years

Inclusion criteria

Inclusion criteria: Parental consent Lack of nausea and vomiting for other reasons No history of radiotherapy No history of allergies No history of other disease

Exclusion criteria

Exclusion criteria: Drug sensitivity

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: After the intervention for three days. Method of measurement: Parents' statements.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Jafari

Iran University of Medical Sciences

dr.masoumeh.jafari@gmail.com+98 21 2304 6253

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026